UY33886A - Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih - Google Patents

Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih

Info

Publication number
UY33886A
UY33886A UY0001033886A UY33886A UY33886A UY 33886 A UY33886 A UY 33886A UY 0001033886 A UY0001033886 A UY 0001033886A UY 33886 A UY33886 A UY 33886A UY 33886 A UY33886 A UY 33886A
Authority
UY
Uruguay
Prior art keywords
triterpenoids
modified
inhibiting activity
hiv maturation
compounds
Prior art date
Application number
UY0001033886A
Other languages
English (en)
Inventor
Liu Zheng
Swidorski Jacob
Sin Ny
Brian Lee Venables
Sing-Yuen Sit
Chen Jie
Nicholas A Meanwell
Chen Yan
Alicia Regueiro-Ren
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY33886A publication Critical patent/UY33886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que tienen propiedades farmacológicas y que afectan el aspecto biológico, sus composiciones farmacéuticas y métodos de uso. En particular, los triterpenoides C-17 y C-3 modificados que tienen una actividad antiviral única se proveen como inhibidores de la maduración del VIH, como se representa mediante los compuestos de las Fórmulas I, II y III. Estos compuestos son útiles para el tratamiento del VIH y del SIDA
UY0001033886A 2011-01-31 2012-01-31 Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih UY33886A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31

Publications (1)

Publication Number Publication Date
UY33886A true UY33886A (es) 2012-07-31

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033886A UY33886A (es) 2011-01-31 2012-01-31 Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih

Country Status (24)

Country Link
US (3) US8846647B2 (es)
EP (1) EP2670765B1 (es)
JP (1) JP6001560B2 (es)
KR (1) KR101886467B1 (es)
CN (1) CN103429607B (es)
AR (1) AR085053A1 (es)
AU (1) AU2012212509B2 (es)
BR (1) BR112013019419A2 (es)
CA (1) CA2826113C (es)
CL (1) CL2013002185A1 (es)
CO (1) CO6751275A2 (es)
EA (1) EA022470B1 (es)
ES (1) ES2653847T3 (es)
IL (1) IL227678B (es)
MA (1) MA34909B1 (es)
MY (1) MY162186A (es)
PE (1) PE20141152A1 (es)
PT (1) PT2670765T (es)
SG (1) SG192144A1 (es)
TN (1) TN2013000321A1 (es)
TW (1) TWI628188B (es)
UY (1) UY33886A (es)
WO (1) WO2012106190A1 (es)
ZA (1) ZA201306546B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019263B1 (ru) 2008-04-18 2014-02-28 Ритэ Фамэсутикл, Инк. Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
PL2670764T3 (pl) * 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
ME03469B (me) 2011-03-11 2020-01-20 Reata Pharmaceuticals Inc DERIVATI C4-MONOMETIL TRITERPENOIDA l POSTUPCI ZA NJIHOVU UPOTREBU
KR20140069167A (ko) 2011-09-21 2014-06-09 브리스톨-마이어스 스큅 컴퍼니 항바이러스 활성을 갖는 신규 베툴린산 유도체
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
KR20150043465A (ko) * 2012-08-15 2015-04-22 글락소 그룹 리미티드 화학 공정
EP2892912B1 (en) 2012-09-10 2019-04-24 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CA2900124A1 (en) * 2013-02-06 2014-08-14 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体
HUE051719T2 (hu) 2014-04-11 2021-03-29 Viiv Healthcare Uk No 4 Ltd Triterpenoidok HIV érésgátló aktivitással, amelyek a 3-helyzetben egy halogénalkil-szubsztituenst hordozó nem-aromás gyûrûvel helyettesítettek
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
CA2967684A1 (en) * 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
BR112017021936A2 (pt) 2015-04-14 2018-07-10 Viiv Healthcare Uk No 4 Ltd método para produção de um composto
JP2018521107A (ja) 2015-07-28 2018-08-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ感染を予防または治療するためのベツイン誘導体
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
ES2865163T3 (es) 2015-09-23 2021-10-15 Reata Pharmaceuticals Inc Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos
WO2017051355A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
US20200268772A1 (en) 2015-11-20 2020-08-27 ViiV Healthcare UK (No.4) Limited Hiv maturation inhibitor formulations
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
BR112020002322A2 (pt) 2017-08-04 2020-09-01 Ardelyx, Inc. derivados de ácido glicirretinínico para o tratamento de hipercalemia
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
PT3784349T (pt) 2018-04-24 2024-01-22 Viiv Healthcare Uk No 5 Ltd Compostos com atividade inibidora de maturação do hiv
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020165741A1 (en) 2019-02-11 2020-08-20 Hetero Labs Limited Novel triterpene derivatives as hiv inhibitors
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009100532A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
US9067966B2 (en) * 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
PL2576586T3 (pl) * 2010-06-04 2016-01-29 Bristol Myers Squibb Co C-28 amidy zmodyfikowanych pochodnych kwasu C-3 betulinowego jako inhibitory dojrzewania HIV
EA022393B1 (ru) * 2010-06-04 2015-12-30 Бристол-Майерс Сквибб Компани С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич

Also Published As

Publication number Publication date
ES2653847T3 (es) 2018-02-09
IL227678A0 (en) 2013-09-30
TW201309717A (zh) 2013-03-01
AU2012212509B2 (en) 2016-01-21
US20140343000A1 (en) 2014-11-20
JP6001560B2 (ja) 2016-10-05
TN2013000321A1 (en) 2015-01-20
CO6751275A2 (es) 2013-09-16
CA2826113A1 (en) 2012-08-09
CN103429607B (zh) 2016-02-17
EA022470B1 (ru) 2016-01-29
CA2826113C (en) 2018-09-04
EP2670765A1 (en) 2013-12-11
US8846647B2 (en) 2014-09-30
NZ614871A (en) 2014-06-27
KR20140016279A (ko) 2014-02-07
CN103429607A (zh) 2013-12-04
SG192144A1 (en) 2013-08-30
JP2014503595A (ja) 2014-02-13
KR101886467B1 (ko) 2018-08-07
EA201391127A1 (ru) 2013-12-30
AU2012212509A1 (en) 2013-09-19
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
EP2670765B1 (en) 2017-10-18
MY162186A (en) 2017-05-31
IL227678B (en) 2018-04-30
PT2670765T (pt) 2018-01-08
BR112013019419A2 (pt) 2019-12-03
PE20141152A1 (es) 2014-09-22
TWI628188B (zh) 2018-07-01
US20130035318A1 (en) 2013-02-07
MA34909B1 (fr) 2014-02-01
CL2013002185A1 (es) 2013-12-27
AR085053A1 (es) 2013-08-07

Similar Documents

Publication Publication Date Title
UY33886A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
EA201591545A1 (ru) C-3 алкил- и алкенил-модифицированные производные бетулиновой кислоты
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY35213A (es) Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
ECSP18010481A (es) Composiciones de plinabulina
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
DOP2011000260A (es) Pirimidinas fusionadas
ECSP14013215A (es) Compuestos novedosos
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
CO2018008157A2 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CU20170102A7 (es) Nueva triterpenona c-3 con derivados de amida reversa c-17 como inhibidores de vih
SV2015005126A (es) Nuevos compuestos para el tratamiento del cáncer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211006